Should I Buy TERN? TERN 2026 Analysis

Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

44.290

1 Day change

-5.32%

52 Week Range

48.260

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Terns Pharmaceuticals Inc (TERN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has strong analyst support and promising drug development, the stock's recent price surge and overbought technical indicators suggest limited immediate upside. Additionally, the financial performance is weak, and there are no strong trading signals or significant insider activity to justify immediate action.

Technical Analysis

The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive, indicating an uptrend. However, the RSI at 70.862 is near overbought territory, suggesting limited room for further short-term gains. Key resistance levels are at 43.402 and 44.601, while support levels are at 39.521 and 38.322.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, but the implied volatility rank of 4.19 suggests limited potential for significant price movement in the near term.

Technical Summary

Sell

Buy

Positive Catalysts

Strong analyst ratings with multiple price target increases, including a high of $60, reflecting confidence in TERN-701's potential as a best-in-class treatment for chronic myeloid leukemia.
Boxer Capital Management's recent acquisition of 375,000 shares, signaling institutional confidence.
Promising clinical trial results for TERN-701, showing high efficacy and safety profiles.

Neutral/Negative Catalysts

The stock has already surged 858.4% over the past year, potentially limiting further upside in the near term.
Weak financial performance, with no revenue and negative net income (-$24.6M in Q3 2025).
Stock trend analysis predicts a potential decline of -1.65% in the next week and -10.15% in the next month.

Financial Performance

The company's financials for Q3 2025 show no revenue growth (0% YoY), a net income loss of -$24.6M (improved by 12.26% YoY), and a declining EPS of -0.27 (-3.57% YoY). Gross margin remains at 0%, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly optimistic, with multiple firms raising price targets to $54-$60 and maintaining Outperform/Buy ratings. The optimism is driven by the promising clinical trial results of TERN-701 and its potential to capture significant market share in the chronic myeloid leukemia space.

11 Analyst Rating

Wall Street analysts forecast TERN stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 46.780

Low

Averages

54.22

High

Current: 46.780

Low

Averages

54.22

High

Leerink

Outperform

initiated

$58

AI Analysis

2026-02-09

Reason

Leerink

Price Target

$58

AI Analysis

2026-02-09

initiated

Outperform

Reason

Leerink initiated coverage of Terns Pharmaceuticals with an Outperform rating and $58 price target. Terns is a clinical-stage biotechnology company developing TERN-701, a next-generation allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia. Early phase 1 TERN-701 CARDINAL data suggest a best-in-class profile, with materially higher molecular response rates and a clean safety profile that affords a wider therapeutic window enabling deeper and more durable target suppression, the firm notes. The frontline CML setting is the primary driver of value for TERN-701, which Leerink sees as a $4.8B opportunity, $32/share in its model. At Terns's current $4B market valuation, conviction in TERN-701's ability to meaningfully penetrate the frontline setting is paramount to the long thesis. The firm forecasts an additional $1.4B of second-line-and-beyond peak revenues or $18/share in its model.

Citizens

Outperform

maintain

$35 -> $57

2025-12-11

Reason

Citizens

Price Target

$35 -> $57

2025-12-11

maintain

Outperform

Reason

Citizens raised the firm's price target on Terns Pharmaceuticals to $57 from $35 and keeps an Outperform rating on the shares. Terns' interim Phase 1 CARDINAL ASH update highlighted the best-in-class profile of TERN-701, the analyst tells investors in a research note. Key additional data points were the high deep molecular response rate, setting it up well in 1L, and the strong activity post asciminib and ponatinib, which is very positive in 2L, Citizens says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TERN

Unlock Now

TERN Should I Buy

TERN Should I Buy

Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch